[1] [3] As a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide works by enhancing insulin secretion in response to meals, suppressing glucagon release, slowing gastric emptying, and reducing appetite
It was originally isolated from human plasma in 1973 and is one of the most extensively studied copper peptides in published research literature
Not everyone needs the same supplement routine, but many GLP-1 users include at least basic nutritional support
[1] [2] It is important for patients to maintain regular follow-up appointments with their diabetes care team, typically every 36 months, to monitor glycaemic control, assess tolerability, and review the ongoing appropriateness of treatment
We briefly touch upon some of the available information for upcoming drugs below, both in the US and abroad: Tern Pharmaceutical (TERN): TERN-601 TERN-601 is a preclinical GLP1R agonist , which in mice has been shown to be able to reduce food intake, slow gastric emptying and improve glucose tolerance
Barton-Davis, Shoturma, & Sweeney
